JP2011504485A - Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途 - Google Patents

Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途 Download PDF

Info

Publication number
JP2011504485A
JP2011504485A JP2010534558A JP2010534558A JP2011504485A JP 2011504485 A JP2011504485 A JP 2011504485A JP 2010534558 A JP2010534558 A JP 2010534558A JP 2010534558 A JP2010534558 A JP 2010534558A JP 2011504485 A JP2011504485 A JP 2011504485A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
amine
fluoro
fluorobut
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010534558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011504485A5 (enExample
Inventor
マクドナルド，イアン，アレクサンダー
ターナー，クレイグ，イヴァン
デオダール，マンダー
フット，ジョナサン，スチュアート
Original Assignee
ファーマクシス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマクシス リミテッド filed Critical ファーマクシス リミテッド
Publication of JP2011504485A publication Critical patent/JP2011504485A/ja
Publication of JP2011504485A5 publication Critical patent/JP2011504485A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/46—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/54—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/27—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010534558A 2007-11-21 2008-11-19 Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途 Pending JP2011504485A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98963407P 2007-11-21 2007-11-21
PCT/IB2008/003124 WO2009066152A2 (en) 2007-11-21 2008-11-19 Haloallylamine inhibitors of ssao/vap-1 and uses therefor

Publications (2)

Publication Number Publication Date
JP2011504485A true JP2011504485A (ja) 2011-02-10
JP2011504485A5 JP2011504485A5 (enExample) 2011-05-26

Family

ID=40667907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010534558A Pending JP2011504485A (ja) 2007-11-21 2008-11-19 Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途

Country Status (10)

Country Link
US (1) US8426587B2 (enExample)
EP (1) EP2222160B1 (enExample)
JP (1) JP2011504485A (enExample)
CN (1) CN101917845A (enExample)
AU (1) AU2008327615B2 (enExample)
CA (1) CA2706465A1 (enExample)
NZ (1) NZ585528A (enExample)
SG (1) SG186008A1 (enExample)
WO (1) WO2009066152A2 (enExample)
ZA (1) ZA201003596B (enExample)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015521167A (ja) * 2012-05-02 2015-07-27 ファームアクシス・リミテッドＰｈａｒｍａｘｉｓ Ｌｔｄ Ｓｓａｏの置換３−ハロアリルアミン阻害剤およびその使用
JP2019504899A (ja) * 2016-02-12 2019-02-21 ファーマクシス リミテッド リジルオキシダーゼのインドールおよびアザインドールハロアリルアミン誘導体阻害剤およびその使用
JP2020507589A (ja) * 2017-02-14 2020-03-12 イーライ リリー アンド カンパニー Ｓｓａｏ阻害剤として有用なアミノピリミジン化合物
JP2020524158A (ja) * 2017-06-20 2020-08-13 山東丹紅制薬有限公司Ｓｈａｎｄｏｎｇ Ｄａｎｈｏｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Ｓｓａｏ阻害剤
KR20210045984A (ko) * 2018-08-03 2021-04-27 파맥시스 엘티디 라이실 옥시다제의 할로알릴아민 설폰 유도체 저해제 및 이의 용도
JP2021529773A (ja) * 2018-07-03 2021-11-04 ユハン コーポレーションＹｕｈａｎ Ｃｏｒｐｏｒａｔｉｏｎ （ｅ）−（２−（クロロメチル）−３−フルオロアリル）カルバメート化合物を調製するためのプロセス
JP2022511374A (ja) * 2018-09-28 2022-01-31 アキュセラ インコーポレイテッド Ｖａｐ－１の阻害剤
JP2022544031A (ja) * 2019-07-25 2022-10-17 ファーマクシス リミテッド リシルオキシダーゼのジフルオロハロアリルアミンスルホン誘導体阻害剤、調製方法、及びそれらの使用
JP2022554330A (ja) * 2019-10-29 2022-12-28 エコジーン （シャンハイ） カンパニー リミテッド Ｓｓａｏ阻害剤およびその使用
JP2023531468A (ja) * 2020-06-26 2023-07-24 ファーマクシス リミテッド ハロアリルアミン系二重アミンオキシダーゼ阻害剤
US11724982B2 (en) 2014-10-10 2023-08-15 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
US11820754B2 (en) 2020-08-25 2023-11-21 Eli Lilly And Company Polymorphs of an SSAO inhibitor

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112154C2 (uk) * 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
FI20115234A0 (fi) 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014199171A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
JP2019502672A (ja) 2015-12-07 2019-01-31 ベネボレンタイ ケンブリッジ リミティド 疼痛の治療のためのｖａｐ−１阻害剤
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
GB201617339D0 (en) 2016-10-12 2016-11-23 Lytix Biopharma As Therapeutic compounds
MX2019004549A (es) 2016-10-19 2019-06-12 Boehringer Ingelheim Int Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos.
AU2018226955B2 (en) * 2017-03-01 2021-02-18 Boehringer Ingelheim International Gmbh Transition metal-catalyzed protodecarboxylation of α-halo-acrylic acid derivatives
EP3589619A4 (en) * 2017-03-02 2020-12-16 Pharmaxis Ltd. LYSYL OXIDASE INHIBITORS, HALOGENOALLYLAMINE PYRAZOLE DERIVATIVES AND THEIR USES
US20200087248A1 (en) * 2017-04-28 2020-03-19 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Fluoroallylamine Derivative And Use Thereof
WO2019024924A1 (zh) * 2017-08-04 2019-02-07 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
CN109810041B (zh) * 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN109988109B (zh) * 2017-12-29 2020-12-29 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其用途
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
WO2020006177A1 (en) * 2018-06-29 2020-01-02 Blade Therapeutics, Inc. Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof
CN110938059A (zh) * 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
CN113164489A (zh) 2018-09-28 2021-07-23 奥克塞拉有限公司 Vap-1的抑制剂
US20220002309A1 (en) * 2018-10-24 2022-01-06 Metacrine, Inc. Ssao inhibitors and uses thereof
TWI835945B (zh) 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
EP3892621B1 (en) 2019-01-11 2024-09-18 TransThera Sciences (Nanjing), Inc. Haloallylamine compounds and application thereof
US12258317B2 (en) 2019-05-20 2025-03-25 Sunshine Lake Pharma Co., Ltd. Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof
CN112876419A (zh) * 2019-11-29 2021-06-01 四川科伦博泰生物医药股份有限公司 烯丙胺衍生物及其制备方法和用途
US20230349907A1 (en) * 2020-02-05 2023-11-02 Pharmaxis Ltd. Bioprobes for lysyl oxidases and uses thereof
CN114621190B (zh) * 2020-12-14 2023-12-05 上海拓界生物医药科技有限公司 一种烯丙基胺类衍生物及其用途
CN114621189B (zh) * 2020-12-14 2024-01-02 上海拓界生物医药科技有限公司 一种内酰胺类衍生物及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD246990A1 (de) * 1986-02-26 1987-06-24 Univ Leipzig Verfahren zur herstellung von gamma-chlorallylverbindungen aus polychloralkanen
US5565602A (en) * 1995-03-13 1996-10-15 Phillips Petroleum Company Production of thiolcarbamates
WO2005121155A1 (en) * 2004-06-09 2005-12-22 F.I.S. Fabbrica Italiana Sintetici S.P.A. A process for the synthesis of terbinafine and derivatives thereof
WO2007005737A2 (en) * 2005-07-01 2007-01-11 Case Western Reserve University Amine oxidase inhibitors
JP2007509605A (ja) * 2003-05-26 2007-04-19 バイオティ セラピーズ コーポレイション 結晶性タンパク質ｖａｐ−１その用途
JP2007523955A (ja) * 2004-02-25 2007-08-23 ラ ホヤ ファーマシューティカル カンパニー 疾患の治療のためのアミンおよびアミド
WO2007120528A2 (en) * 2006-03-31 2007-10-25 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4454158A (en) 1981-06-01 1984-06-12 Merrell Toraude Et Compagnie Allyl amine MAO inhibitors
DE3129826A1 (de) * 1981-07-29 1983-04-28 Grillo-Werke Ag, 4100 Duisburg Zinksalz der hydrolisierten tricarbonsaeure aus diels-alder-addukten von maleinsaeureanhydrid an undecylensaeure, verfahren zur herstellung derselben und ihre verwendung
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4650907A (en) 1985-12-05 1987-03-17 Merrell Dow Pharmaceuticals Inc. Nonaromatic fluoroallylamine MAO inhibitors
AU618076B2 (en) 1988-02-25 1991-12-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyloxidase
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5578289A (en) 1992-03-04 1996-11-26 Akzo N.V. In vivo binding pair pretargeting
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
DE4438017C2 (de) 1994-10-25 1996-10-31 Bosch Gmbh Robert Verfahren und Vorrichtung zur elektrischen Steuerung bzw. Regelung der Bremsanlage eines Fahrzeugs
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US6139865A (en) 1996-10-01 2000-10-31 Eurand America, Inc. Taste-masked microcapsule compositions and methods of manufacture
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
JP3333101B2 (ja) * 1996-11-27 2002-10-07 シャープ株式会社 光結合器の製造方法
US5860674A (en) * 1997-01-31 1999-01-19 Robert Bosch Corporation AOS fan modulation systems
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CN1152673C (zh) 1997-10-28 2004-06-09 坂东化学株式会社 皮肤贴附药片及其基片的制造方法
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6256633B1 (en) * 1998-06-25 2001-07-03 U.S. Philips Corporation Context-based and user-profile driven information retrieval
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
CA2414807A1 (en) 2000-07-05 2002-01-10 Markku Jalkanen Inhibitors of copper-containing amine oxidases
GB2408071B (en) 2002-08-17 2005-10-19 Siemens Magnet Technology Ltd Pressure relief valve for a helium gas compressor
WO2004018997A2 (en) 2002-08-20 2004-03-04 Neurogenetics, Inc. Methods and compositions for modulating amyloid beta
WO2004087138A1 (en) * 2003-03-31 2004-10-14 Sucampo Ag Method for treating vascular hyperpermeable disease
CN1921841A (zh) * 2004-02-25 2007-02-28 拉卓拉药物公司 用于治疗疾病的胺和酰胺类化合物
WO2006094201A2 (en) 2005-03-02 2006-09-08 La Jolla Pharmaceutical Company Semicarbazide-sensitive amide oxidase inhibitors
US20070021365A1 (en) 2005-06-21 2007-01-25 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto
US7540564B2 (en) 2006-03-30 2009-06-02 Esther Gokhale Ergonomic systems and devices

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD246990A1 (de) * 1986-02-26 1987-06-24 Univ Leipzig Verfahren zur herstellung von gamma-chlorallylverbindungen aus polychloralkanen
US5565602A (en) * 1995-03-13 1996-10-15 Phillips Petroleum Company Production of thiolcarbamates
JP2007509605A (ja) * 2003-05-26 2007-04-19 バイオティ セラピーズ コーポレイション 結晶性タンパク質ｖａｐ−１その用途
JP2007523955A (ja) * 2004-02-25 2007-08-23 ラ ホヤ ファーマシューティカル カンパニー 疾患の治療のためのアミンおよびアミド
WO2005121155A1 (en) * 2004-06-09 2005-12-22 F.I.S. Fabbrica Italiana Sintetici S.P.A. A process for the synthesis of terbinafine and derivatives thereof
WO2007005737A2 (en) * 2005-07-01 2007-01-11 Case Western Reserve University Amine oxidase inhibitors
WO2007120528A2 (en) * 2006-03-31 2007-10-25 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, no. 15, JPN6013028462, 2002, pages 1917 - 1919, ISSN: 0002555737 *
JOURNAL FUER PRAKTISCHE CHEMIE, vol. 320, no. 1, JPN6013028456, 1978, pages 143 - 150, ISSN: 0002555734 *
JOURNAL OF ORGANIC CHEMISTRY, vol. 27, JPN6013028461, 1962, pages 3688 - 3690, ISSN: 0002555736 *
JOURNAL OF ORGANIC CHEMISTRY, vol. 35, no. 4, JPN6013028458, 1970, pages 1086 - 1092, ISSN: 0002555735 *
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 81, JPN6013028451, 1959, pages 714 - 727, ISSN: 0002555732 *
ORGANIC LETTERS, vol. 3, no. 21, JPN6013028453, 2001, pages 3377 - 3379, ISSN: 0002555733 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017132767A (ja) * 2012-05-02 2017-08-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｓａｏの置換３−ハロアリルアミン阻害剤およびその使用
JP2015521167A (ja) * 2012-05-02 2015-07-27 ファームアクシス・リミテッドＰｈａｒｍａｘｉｓ Ｌｔｄ Ｓｓａｏの置換３−ハロアリルアミン阻害剤およびその使用
US11724982B2 (en) 2014-10-10 2023-08-15 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
JP2019504899A (ja) * 2016-02-12 2019-02-21 ファーマクシス リミテッド リジルオキシダーゼのインドールおよびアザインドールハロアリルアミン誘導体阻害剤およびその使用
JP2019504898A (ja) * 2016-02-12 2019-02-21 ファーマクシス リミテッド リジルオキシダーゼのハロアリルアミンインドールおよびアザインドール誘導体阻害剤およびその使用
JP7030827B2 (ja) 2017-02-14 2022-03-07 イーライ リリー アンド カンパニー Ｓｓａｏ阻害剤として有用なアミノピリミジン化合物
JP2020507589A (ja) * 2017-02-14 2020-03-12 イーライ リリー アンド カンパニー Ｓｓａｏ阻害剤として有用なアミノピリミジン化合物
JP7247389B2 (ja) 2017-02-14 2023-03-28 イーライ リリー アンド カンパニー Ｓｓａｏ阻害剤として有用なアミノピリミジン化合物
JP2022068325A (ja) * 2017-02-14 2022-05-09 イーライ リリー アンド カンパニー Ｓｓａｏ阻害剤として有用なアミノピリミジン化合物
US11505532B2 (en) 2017-06-20 2022-11-22 Shandong Danhong Pharmaceutical Co., Ltd. SSAO inhibitor
US11001563B2 (en) 2017-06-20 2021-05-11 Shandong Danhong Pharmaceutical Co., Ltd. SSAO inhibitor
JP2020524158A (ja) * 2017-06-20 2020-08-13 山東丹紅制薬有限公司Ｓｈａｎｄｏｎｇ Ｄａｎｈｏｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Ｓｓａｏ阻害剤
JP2021529773A (ja) * 2018-07-03 2021-11-04 ユハン コーポレーションＹｕｈａｎ Ｃｏｒｐｏｒａｔｉｏｎ （ｅ）−（２−（クロロメチル）−３−フルオロアリル）カルバメート化合物を調製するためのプロセス
JP7128914B2 (ja) 2018-07-03 2022-08-31 ユハン コーポレーション （ｅ）－（２－（クロロメチル）－３－フルオロアリル）カルバメート化合物を調製するためのプロセス
JP2021535087A (ja) * 2018-08-03 2021-12-16 ファーマクシス リミテッド リシルオキシダーゼのハロアリルアミンスルホン誘導体阻害剤およびそれらの使用
JP7414803B2 (ja) 2018-08-03 2024-01-16 ファーマクシス リミテッド リシルオキシダーゼのハロアリルアミンスルホン誘導体阻害剤およびそれらの使用
KR102780601B1 (ko) * 2018-08-03 2025-03-12 파맥시스 엘티디 라이실 옥시다제의 할로알릴아민 설폰 유도체 저해제 및 이의 용도
KR20210045984A (ko) * 2018-08-03 2021-04-27 파맥시스 엘티디 라이실 옥시다제의 할로알릴아민 설폰 유도체 저해제 및 이의 용도
JP2022511374A (ja) * 2018-09-28 2022-01-31 アキュセラ インコーポレイテッド Ｖａｐ－１の阻害剤
US12162871B2 (en) 2018-09-28 2024-12-10 Acucela Inc. Inhibitors of VAP-1
US11787791B2 (en) 2018-09-28 2023-10-17 Acucela Inc. Inhibitors of VAP-1
JP7515467B2 (ja) 2018-09-28 2024-07-12 アキュセラ インコーポレイテッド Ｖａｐ－１の阻害剤
JP2022544031A (ja) * 2019-07-25 2022-10-17 ファーマクシス リミテッド リシルオキシダーゼのジフルオロハロアリルアミンスルホン誘導体阻害剤、調製方法、及びそれらの使用
JP2022554330A (ja) * 2019-10-29 2022-12-28 エコジーン （シャンハイ） カンパニー リミテッド Ｓｓａｏ阻害剤およびその使用
JP7703272B2 (ja) 2019-10-29 2025-07-07 エコジーン インコーポレイテッド Ｓｓａｏ阻害剤およびその使用
JP2023531468A (ja) * 2020-06-26 2023-07-24 ファーマクシス リミテッド ハロアリルアミン系二重アミンオキシダーゼ阻害剤
JP7665122B2 (ja) 2020-06-26 2025-04-21 シンタラ リミテッド ハロアリルアミン系二重アミンオキシダーゼ阻害剤
US11820754B2 (en) 2020-08-25 2023-11-21 Eli Lilly And Company Polymorphs of an SSAO inhibitor

Also Published As

Publication number Publication date
CA2706465A1 (en) 2009-05-28
EP2222160A2 (en) 2010-09-01
AU2008327615B2 (en) 2014-08-21
CN101917845A (zh) 2010-12-15
EP2222160A4 (en) 2011-02-16
NZ585528A (en) 2012-08-31
ZA201003596B (en) 2011-02-23
SG186008A1 (en) 2012-12-28
WO2009066152A3 (en) 2009-12-30
AU2008327615A1 (en) 2009-05-28
US20100298330A1 (en) 2010-11-25
US8426587B2 (en) 2013-04-23
EP2222160B1 (en) 2015-03-18
WO2009066152A2 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
JP2011504485A (ja) Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途
US10160723B2 (en) Substituted 3-haloallylamine inhibitors of SSAO and uses thereof
JP2008524244A (ja) 水酸化ステロイド脱水素酵素阻害剤
CS225850B2 (en) Process for preparing new r,r-n-(2-phenyl-2-hydroxyethyl)-1-methyl-3-phenylpropylamines
US20250074904A1 (en) Nsd2-targeted checmical degraderts and compositions and methods of use thereof
US7084301B2 (en) Tamsulosin derivative
WO2021115372A1 (zh) 一种沃替西汀前药及其应用
WO2024258904A1 (en) Tetrahydroacridinone analogues for treatment and prevention of malaria
JP2005511687A (ja) プロパノールアミノメチルテトラリン、それらの製造方法およびそれらを含む医薬組成物
JP2005511687A6 (ja) プロパノールアミノメチルテトラリン、それらの製造方法およびそれらを含む医薬組成物
HK1245237B (zh) Ssao的取代的3-卤代烯丙基胺抑制剂及其用途
HK1203477B (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110405

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131224